Research
Hormonal
Semaglutide therapy resulted in a 62.9% resolution of MASH without worsening of fibrosis compared to 34.3% in placebo (p <0.001).
Clinicians can consider semaglutide as an effective treatment option for MASH with moderate-to-advanced fibrosis.
StrongSupportsmedium confidence
72 weeks of 2.4 mg/week subcutaneous injection resulted in achievement of both primary histologic endpoints: (1) resolution of MASH without worsening of fibrosis (62.9% vs. 34.3% placebo, p <0.001)
Why this rating
Based on interim results of a phase 3 trial.
Source
Semaglutide therapy for metabolic dysfunction–associated steatohepatitis: November 2025 updates to AASLD Practice Guidance
Meena B. Bansal et al. · Hepatology · 2025
otherCited 32×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →